Poly-SUMO-2/3 chain modification of Nuf2 facilitates CENP-E kinetochore localization and chromosome congression during mitosis

References

• Abrieu A, Liakopoulos D. How does SUMO participate in spindle organization? Cells. 2019;8:801.
   Web of Science ®Google Scholar
• Dasso M. Emerging roles of the SUMO pathway in mitosis. Cell Div. 2008;3:5.
   PubMed Web of Science ®Google Scholar
• Wan J, Subramonian D, Zhang XD. SUMOylation in control of accurate chromosome segregation during mitosis. Curr Protein Pept Sci. 2012;13:467–481.
   PubMed Web of Science ®Google Scholar
• Wang Y, Dasso M. SUMOylation and deSUMOylation at a glance. J Cell Sci. 2009;122:4249–4252.
   PubMed Web of Science ®Google Scholar
• Bernier-Villamor V, Sampson DA, Matunis MJ, et al. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell. 2002;108:345–356.
   PubMed Web of Science ®Google Scholar
• Rodriguez MS, Dargemont C, Hay RT. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem. 2001;276(16):12654–12659.
   PubMed Web of Science ®Google Scholar
• Sampson DA, Wang M, Matunis MJ. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem. 2001;276(24):21664–21669.
   PubMed Web of Science ®Google Scholar
• Pedrioli PG, Raught B, Zhang XD, et al. Automated identification of SUMOylation sites using mass spectrometry and SUMmOn pattern recognition software. Nat Methods. 2006;3:533–539.
   PubMed Web of Science ®Google Scholar
• Tatham MH, Jaffray E, Vaughan OA, et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem. 2001;276:35368–35374.
   PubMed Web of Science ®Google Scholar
• Vertegaal AC. Small ubiquitin-related modifiers in chains. Biochem Soc Trans. 2007;35:1422–1423.
   PubMed Web of Science ®Google Scholar
• Matic I, Van Hagen M, Schimmel J, et al. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol Cell Proteomics. 2008;7:132–144.
   PubMed Web of Science ®Google Scholar
• Zhang XD, Goeres J, Zhang H, et al. SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol Cell. 2008;29:729–741.
   PubMed Web of Science ®Google Scholar
• Cheeseman IM. The kinetochore. Cold Spring Harb Perspect Biol. 2014;6:a015826.
   PubMed Web of Science ®Google Scholar
• Maiato H, DeLuca J, Salmon ED, et al. The dynamic kinetochore-microtubule interface. J Cell Sci. 2004;117:5461–5477.
   PubMed Web of Science ®Google Scholar
• Abrieu A, Kahana JA, Wood KW, et al. CENP-E as an essential component of the mitotic checkpoint in vitro. Cell. 2000;102(6):817–826.
   PubMed Web of Science ®Google Scholar
• Azuma Y, Arnaoutov A, Dasso M. SUMO-2/3 regulates topoisomerase II in mitosis. J Cell Biol. 2003;163:477–487.
   PubMed Web of Science ®Google Scholar
• Ban R, Nishida T, Urano T. Mitotic kinase Aurora-B is regulated by SUMO-2/3 conjugation/deconjugation during mitosis. Genes Cells. 2011;16:652–669.
   PubMed Web of Science ®Google Scholar
• Li T, Chen L, Cheng J, et al. SUMOylated NKAP is essential for chromosome alignment by anchoring CENP-E to kinetochores. Nat Commun. 2016;7(1):12969.
   PubMedGoogle Scholar
• Mukhopadhyay D, Arnaoutov A, Dasso M. The SUMO protease SENP6 is essential for inner kinetochore assembly. J Cell Biol. 2010;188(5):681–692.
   PubMed Web of Science ®Google Scholar
• Restuccia A, Yang F, Chen C, et al. Mps1 is SUMO-modified during the cell cycle. Oncotarget. 2016;7(3):3158–3170.
   PubMedGoogle Scholar
• Yang F, Hu L, Chen C, et al. BubR1 is modified by sumoylation during mitotic progression. J Biol Chem. 2012;287:4875–4882.
   PubMed Web of Science ®Google Scholar
• Agostinho M, Santos V, Ferreira F, et al. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity. Cancer Res. 2008;68:2409–2418.
   PubMed Web of Science ®Google Scholar
• Joseph J, Liu ST, Jablonski SA, et al. The RanGAP1-RanBP2 complex is essential for microtubule-kinetochore interactions in vivo. Curr Biol. 2004;14:611–617.
   PubMed Web of Science ®Google Scholar
• Seufert W, Futcher B, Jentsch S. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature. 1995;373(6509):78–81.
   PubMed Web of Science ®Google Scholar
• Cubenas-Potts C, Goeres JD, Matunis MJ. SENP1 and SENP2 affect spatial and temporal control of sumoylation in mitosis. Mol Biol Cell. 2013;24:3483–3495.
   PubMed Web of Science ®Google Scholar
• Chan GK, Schaar BT, Yen TJ. Characterization of the kinetochore binding domain of CENP-E reveals interactions with the kinetochore proteins CENP-F and hBUBR1. J Cell Biol. 1998;143:49–63.
   PubMed Web of Science ®Google Scholar
• Cooke CA, Schaar B, Yen TJ, et al. Localization of CENP-E in the fibrous corona and outer plate of mammalian kinetochores from prometaphase through anaphase. Chromosoma. 1997;106(7):446–455.
   PubMed Web of Science ®Google Scholar
• Yen TJ, Compton DA, Wise D, et al. CENP-E, a novel human centromere-associated protein required for progression from metaphase to anaphase. Embo J. 1991;10:1245–1254.
   PubMed Web of Science ®Google Scholar
• Kapoor TM, Lampson MA, Hergert P, et al. Chromosomes can congress to the metaphase plate before biorientation. Science. 2006;311(5759):388–391.
   PubMed Web of Science ®Google Scholar
• Putkey FR, Cramer T, Morphew MK, et al. Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell. 2002;3(3):351–365.
   PubMed Web of Science ®Google Scholar
• Schaar BT, Chan GK, Maddox P, et al. CENP-E function at kinetochores is essential for chromosome alignment. J Cell Biol. 1997;139(6):1373–1382.
   PubMed Web of Science ®Google Scholar
• Wood KW, Sakowicz R, Goldstein LS, et al. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell. 1997;91:357–366.
   PubMed Web of Science ®Google Scholar
• Liu D, Ding X, Du J, et al. Human NUF2 interacts with centromere-associated protein E and is essential for a stable spindle microtubule-kinetochore attachment. J Biol Chem. 2007;282:21415–21424.
   PubMed Web of Science ®Google Scholar
• DeLuca JG, Moree B, Hickey JM, et al. hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells. J Cell Biol. 2002;159:549–555.
   PubMed Web of Science ®Google Scholar
• Hori T, Haraguchi T, Hiraoka Y, et al. Dynamic behavior of Nuf2-Hec1 complex that localizes to the centrosome and centromere and is essential for mitotic progression in vertebrate cells. J Cell Sci. 2003;116:3347–3362.
   PubMed Web of Science ®Google Scholar
• McCleland ML, Gardner RD, Kallio MJ, et al. The highly conserved Ndc80 complex is required for kinetochore assembly, chromosome congression, and spindle checkpoint activity. Genes Dev. 2003;17:101–114.
   PubMed Web of Science ®Google Scholar
• Jakobs A, Koehnke J, Himstedt F, et al. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation. Nat Methods. 2007;4:245–250.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Deshaies RJ, Chau V. Characterization of a dominant negative mutant of the cell cycle ubiquitin-conjugating enzyme Cdc34. J Biol Chem. 1995;270:26209–26215.
   PubMed Web of Science ®Google Scholar
• Mahajan R, Gerace L, Melchior F. Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association. J Cell Biol. 1998;140:259–270.
   PubMed Web of Science ®Google Scholar
• Matunis MJ, Wu J, Blobel G. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex. J Cell Biol. 1998;140(3):499–509.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Xie Y, Zheng Y, et al. GPS-SUMO: a tool for the prediction of sumoylation sites and SUMO-interaction motifs. Nucleic Acids Res. 2014;42:W325–330.
   PubMed Web of Science ®Google Scholar
• Cox E, Hwang W, Uzoma I, et al. Global analysis of SUMO-binding proteins identifies SUMOylation as a key regulator of the INO80 chromatin remodeling complex. Mol Cell Proteomics. 2017;16:812–823.
   PubMed Web of Science ®Google Scholar
• Legal T, Hayward D, Gluszek-Kustusz A, et al. The C-terminal helix of BubR1 is essential for CENP-E-dependent chromosome alignment. J Cell Sci. 2020;133:jcs246025.
   PubMed Web of Science ®Google Scholar
• Mao Y, Abrieu A, Cleveland DW. Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell. 2003;114:87–98.
   PubMed Web of Science ®Google Scholar
• Sun H, Hunter T. Poly-small ubiquitin-like modifier (PolySUMO)-binding proteins identified through a string search. J Biol Chem. 2012;287:42071–42083.
   PubMed Web of Science ®Google Scholar
• Tatham MH, Geoffroy MC, Shen L, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol. 2008;10:538–546.
   PubMed Web of Science ®Google Scholar
• Eifler K, Cuijpers SAG, Willemstein E, et al. SUMO targets the APC/C to regulate transition from metaphase to anaphase. Nat Commun. 2018;9:1119.
   PubMed Web of Science ®Google Scholar
• Lee CC, Li B, Yu H, et al. Sumoylation promotes optimal APC/C activation and timely anaphase. Elife. 2018;7. DOI:10.7554/eLife.29539
   Web of Science ®Google Scholar
• Liebelt F, Jansen NS, Kumar S, et al. The poly-SUMO2/3 protease SENP6 enables assembly of the constitutive centromere-associated network by group deSUMOylation. Nat Commun. 2019;10:3987.
   PubMed Web of Science ®Google Scholar
• Yang F, Chen Y, Dai W. Sumoylation of Kif18A plays a role in regulating mitotic progression. BMC Cancer. 2015;15:197.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yao Y, Xu HZ, et al. Defects in chromosome congression and mitotic progression in KIF18A-deficient cells are partly mediated through impaired functions of CENP-E. Cell Cycle. 2009;8:2643–2649.
   PubMed Web of Science ®Google Scholar
• Psakhye I, Jentsch S. Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair. Cell. 2012;151(4):807–820.
   PubMed Web of Science ®Google Scholar
• Azuma Y, Arnaoutov A, Anan T, et al. PIASy mediates SUMO-2 conjugation of Topoisomerase-II on mitotic chromosomes. Embo J. 2005;24:2172–2182.
   PubMed Web of Science ®Google Scholar
• Diaz-Martinez LA, Gimenez-Abian JF, Azuma Y, et al. PIASgamma is required for faithful chromosome segregation in human cells. PLoS One. 2006;1:e53.
   PubMed Web of Science ®Google Scholar
• Klein UR, Haindl M, Nigg EA, et al. RanBP2 and SENP3 function in a mitotic SUMO2/3 conjugation-deconjugation cycle on Borealin. Mol Biol Cell. 2009;20(1):410–418.
   PubMed Web of Science ®Google Scholar
• Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem. 2013;82(1):357–385.
   PubMedGoogle Scholar
• Geoffroy MC, Hay RT. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol. 2009;10:564–568.
   PubMed Web of Science ®Google Scholar
• Cuijpers SAG, Willemstein E, Vertegaal ACO. Converging small Ubiquitin-like modifier (SUMO) and Ubiquitin signaling: improved methodology identifies co-modified target proteins. Mol Cell Proteomics. 2017;16:2281–2295.
   PubMed Web of Science ®Google Scholar
• Hendriks IA, Lyon D, Young C, et al. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat Struct Mol Biol. 2017;24:325–336.
   PubMed Web of Science ®Google Scholar
• Erker Y, Neyret-Kahn H, Seeler JS, et al. Arkadia, a novel SUMO-targeted ubiquitin ligase involved in PML degradation. Mol Cell Biol. 2013;33:2163–2177.
   PubMed Web of Science ®Google Scholar
• Geoffroy MC, Jaffray EG, Walker KJ, et al. Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell. 2010;21:4227–4239.
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10:547–555.
   PubMed Web of Science ®Google Scholar
• Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010;328:240–243.
   PubMed Web of Science ®Google Scholar
• He X, Riceberg J, Pulukuri SM, et al. Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation. PLoS One. 2015;10(4):e0123882.
   PubMed Web of Science ®Google Scholar
• Kessler JD, Kahle KT, Sun T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012;335(6066):348–353.
   PubMed Web of Science ®Google Scholar
• Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137:835–848.
   PubMed Web of Science ®Google Scholar
• Eifler K, Vertegaal ACO. SUMOylation-mediated regulation of cell cycle progression and cancer. Trends Biochem Sci. 2015;40:779–793.
   PubMed Web of Science ®Google Scholar
• Seeler JS, Dejean A. SUMO and the robustness of cancer. Nat Rev Cancer. 2017;17:184–197.
   PubMed Web of Science ®Google Scholar
• Subramonian D, Raghunayakula S, Olsen JV, et al. Analysis of changes in SUMO-2/3 modification during breast cancer progression and metastasis. J Proteome Res. 2014;13:3905–3918.
   PubMed Web of Science ®Google Scholar
• Fukuda I, Ito A, Hirai G, et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol. 2009;16:133–140.
   PubMedGoogle Scholar
• He X, Riceberg J, Soucy T, et al. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nat Chem Biol. 2017;13:1164–1171.
   PubMed Web of Science ®Google Scholar
• Hirohama M, Kumar A, Fukuda I, et al. Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2. ACS Chem Biol. 2013;8:2635–2642.
   PubMed Web of Science ®Google Scholar
• Kim YS, Nagy K, Keyser S, et al. An electrophoretic mobility shift assay identifies a mechanistically unique inhibitor of protein sumoylation. Chem Biol. 2013;20(4):604–613.
   PubMedGoogle Scholar
• Li YJ, Du L, Wang J, et al. Allosteric inhibition of Ubiquitin-like modifications by a class of inhibitor of SUMO-activating enzyme. Cell Chem Biol. 2019;26(278–288):e276.
   Google Scholar
• Licciardello MP, Mullner MK, Durnberger G, et al. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene. 2015;34:3780–3790.
   PubMed Web of Science ®Google Scholar
• Lv Z, Yuan L, Atkison JH, et al. Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme. Nat Commun. 2018;9:5145.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Narayan J, Bhattacharyya A, et al. Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets. Cancer Genet. 2017;216-217:37–51.
   PubMed Web of Science ®Google Scholar
• Hayama S, Daigo Y, Kato T, et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res. 2006;66(21):10339–10348.
   PubMed Web of Science ®Google Scholar
• Hu P, Chen X, Sun J, et al. siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep. 2015;35(35). DOI:10.1042/BSR20140124
   Google Scholar
• Huang SK, Qian JX, Yuan BQ, et al. SiRNA-mediated knockdown against NUF2 suppresses tumor growth and induces cell apoptosis in human glioma cells. Cell Mol Biol (Noisy-le-grand). 2014;60:30–36.
   PubMed Web of Science ®Google Scholar
• Shiraishi T, Terada N, Zeng Y, et al. Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med. 2011;9:153.
   PubMed Web of Science ®Google Scholar
• Sun ZY, Wang W, Gao H, et al. Potential therapeutic targets of the nuclear division cycle 80 (NDC80) complexes genes in lung adenocarcinoma. J Cancer. 2020;11:2921–2934.
   PubMed Web of Science ®Google Scholar
• Xu W, Wang Y, Wang Y, et al. Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer. Int J Mol Med. 2019;44:390–404.
   PubMed Web of Science ®Google Scholar
• Kaneko N, Miura K, Gu Z, et al. siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis. Biochem Biophys Res Commun. 2009;390:1235–1240.
   PubMed Web of Science ®Google Scholar
• Liu Q, Dai SJ, Li H, et al. Silencing of NUF2 inhibits tumor growth and induces apoptosis in human hepatocellular carcinomas. Asian Pac J Cancer Prev. 2014;15:8623–8629.
   PubMedGoogle Scholar
• Matunis MJ, Coutavas E, Blobel G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol. 1996;135:1457–1470.
   PubMed Web of Science ®Google Scholar
• Sekhri P, Tao T, Kaplan F, et al. Characterization of amino acid residues within the N-terminal region of Ubc9 that play a role in Ubc9 nuclear localization. Biochem Biophys Res Commun. 2015;458:128–133.
   PubMed Web of Science ®Google Scholar
• Jordan M, Schallhorn A, Wurm FM. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 1996;24: 596–601
   Google Scholar